Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

NCT06384261 is registered in ClinicalTrials.gov with OncoVerity, Inc. as lead sponsor.

NCT NCT06384261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06384261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
Lead sponsor
OncoVerity, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 22, 2024
Completion date
June 30, 2027
Enrollment
140 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute